Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Management of anemia in patients receiving protease inhibitors.

Literature DB >> 22723756

Management of anemia in patients receiving protease inhibitors.

Stephen A Harrison¹.

Abstract

Entities: Disease Species

Year: 2012 PMID： 22723756 PMCID： PMC3380259

Source DB: PubMed Journal: Gastroenterol Hepatol (N Y) ISSN： 1554-7914

× No keyword cloud information.

7 in total

1. Boceprevir for untreated chronic HCV genotype 1 infection.

Authors: Fred Poordad; Jonathan McCone; Bruce R Bacon; Savino Bruno; Michael P Manns; Mark S Sulkowski; Ira M Jacobson; K Rajender Reddy; Zachary D Goodman; Navdeep Boparai; Mark J DiNubile; Vilma Sniukiene; Clifford A Brass; Janice K Albrecht; Jean-Pierre Bronowicki
Journal: N Engl J Med Date: 2011-03-31 Impact factor: 91.245

2. Boceprevir for previously treated chronic HCV genotype 1 infection.

Authors: Bruce R Bacon; Stuart C Gordon; Eric Lawitz; Patrick Marcellin; John M Vierling; Stefan Zeuzem; Fred Poordad; Zachary D Goodman; Heather L Sings; Navdeep Boparai; Margaret Burroughs; Clifford A Brass; Janice K Albrecht; Rafael Esteban
Journal: N Engl J Med Date: 2011-03-31 Impact factor: 91.245

3. Polymorphism of the inosine triphosphate pyrophosphatase gene predicts ribavirin-induced anemia in chronic hepatitis C patients.

Authors: Takashi Nishimura; Rie Osaki; Makoto Shioya; Hirotsugu Imaeda; Tomoki Aomatsu; Takayuki Takeuchi; Yoshiaki Okumura; Yoshihide Fujiyama; Akira Andoh
Journal: Mol Med Rep Date: 2011-11-02 Impact factor: 2.952

Review 4. Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents.

Authors: R Mac Nicholas; S Norris
Journal: Aliment Pharmacol Ther Date: 2010-02-18 Impact factor: 8.171

Review 5. Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis.

Authors: S-M Alavian; S V Tabatabaei; B Behnava
Journal: J Viral Hepat Date: 2011-10-30 Impact factor: 3.728

6. Telaprevir for retreatment of HCV infection.

Authors: Stefan Zeuzem; Pietro Andreone; Stanislas Pol; Eric Lawitz; Moises Diago; Stuart Roberts; Roberto Focaccia; Zobair Younossi; Graham R Foster; Andrzej Horban; Peter Ferenci; Frederik Nevens; Beat Müllhaupt; Paul Pockros; Ruben Terg; Daniel Shouval; Bart van Hoek; Ola Weiland; Rolf Van Heeswijk; Sandra De Meyer; Don Luo; Griet Boogaerts; Ramon Polo; Gaston Picchio; Maria Beumont
Journal: N Engl J Med Date: 2011-06-23 Impact factor: 91.245

7. Telaprevir for previously untreated chronic hepatitis C virus infection.

Authors: Ira M Jacobson; John G McHutchison; Geoffrey Dusheiko; Adrian M Di Bisceglie; K Rajender Reddy; Natalie H Bzowej; Patrick Marcellin; Andrew J Muir; Peter Ferenci; Robert Flisiak; Jacob George; Mario Rizzetto; Daniel Shouval; Ricard Sola; Ruben A Terg; Eric M Yoshida; Nathalie Adda; Leif Bengtsson; Abdul J Sankoh; Tara L Kieffer; Shelley George; Robert S Kauffman; Stefan Zeuzem
Journal: N Engl J Med Date: 2011-06-23 Impact factor: 91.245

7 in total

1 in total

1. Antiretroviral drug class and anaemia risk in the current treatment era among people living with HIV in the USA: a clinical cohort study.

Authors: Barbara N Harding; Bridget M Whitney; Robin M Nance; Heidi M Crane; Greer Burkholder; Richard D Moore; W Christopher Mathews; Joseph J Eron; Peter W Hunt; Paul Volberding; Benigno Rodriguez; Kenneth Mayer; Michael S Saag; Mari M Kitahata; Susan R Heckbert; Joseph A C Delaney
Journal: BMJ Open Date: 2020-03-19 Impact factor: 2.692

1 in total